Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 3
2008 2
2009 1
2010 1
2013 2
2014 2
2015 4
2016 1
2017 2
2018 3
2019 2
2020 3
2021 4
2022 5
2023 7
2024 8
2025 11
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Natarajan K, Sheffield T, Bride D, Arndorfer J, Naleway AL, Koppolu P, Fireman B, Zerbo O, Timbol J, Goddard K, Dixon BE, Fadel WF, Rogerson C, Allen KS, Rao S, Mayer D, Barron M, Reese SE, Rowley EAK, Najdowski M, Ciesla AA, Mak J, Reeves EL, Akinsete OO, McEvoy CE, Essien IJ, Tenforde MW, Fleming-Dutra KE, Link-Gelles R. Payne AB, et al. Among authors: ball sw. Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0. Lancet. 2024. PMID: 39426837
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults.
Link-Gelles R, Rowley EAK, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Dascomb K, Naleway AL, Koppolu P, Zerbo O, Fireman B, Hansen J, Timbol J, Block L, Dixon BE, Duszynski TJ, Allen KS, Mayer D, Chavez C, Barron M, Reese SE, Chickery S, Davis JM, Ciesla AA, Mak J, Najdowski M, Akinsete OO, McEvoy CE, Essien IJ, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Natarajan K, Tenforde MW, DeCuir J, Payne AB. Link-Gelles R, et al. Among authors: ball sw. JAMA Netw Open. 2025 Jun 2;8(6):e2517402. doi: 10.1001/jamanetworkopen.2025.17402. JAMA Netw Open. 2025. PMID: 40560584 Free PMC article.
Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025.
Frutos AM, Cleary S, Reeves EL, Ahmad HM, Price AM, Self WH, Zhu Y, Safdar B, Peltan ID, Gibbs KW, Exline MC, Lauring AS, Ball SW, DeSilva M, Tartof SY, Dascomb K, Irving SA, Klein NP, Dixon BE, Ong TC, Vaughn IA, House SL, Faryar KA, Nowalk MP, Gaglani M, Wernli KJ, Murugan V, Williams OL, Selvarangan R, Weinberg GA, Staat MA, Halasa NB, Sahni LC, Michaels MG, Englund JA, Kirby MK, Surie D, Dawood FS, Clopper BR, Moline HL, Link-Gelles R, Payne AB, Harker E, Wielgosz K, Weber ZA, Yang DH, Lewis NM, DeCuir J, Olson SM, Chung JR, Flannery B, Grohskopf LA, Reed C, Garg S, Ellington S; CDC Influenza Vaccine Effectiveness Collaborators. Frutos AM, et al. Among authors: ball sw. MMWR Morb Mortal Wkly Rep. 2025 Feb 27;74(6):83-90. doi: 10.15585/mmwr.mm7406a2. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40014791 Free PMC article.
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025.
Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Barron MA, Reese SE, McEvoy C, Sheffield T, Naleway AL, Zerbo O, Rogerson C, Self WH, Zhu Y, Lauring AS, Martin ET, Peltan ID, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker ME, Mohamed A, Johnson N, Steingrub JS, Khan A, Felzer JR, Duggal A, Wilson JG, Qadir N, Mallow C, Kwon JH, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Chappell JD, Halasa N, Johnson C, Natarajan K, Lewis NM, Ellington S, Reeves EL, DeCuir J, McMorrow M, Paden CR, Payne AB, Dawood FS, Surie D; CDC COVID-19 Vaccine Effectiveness Collaborators. Link-Gelles R, et al. MMWR Morb Mortal Wkly Rep. 2025 Feb 27;74(6):73-82. doi: 10.15585/mmwr.mm7406a1. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40014628 Free PMC article.
Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025.
Irving SA, Rowley EAK, Chickery S, Natarajan K, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Dascomb K, Naleway AL, Stockwell MS, Stephens AB, Zerbo O, Hansen J, Block L, Jacobson KB, Dixon BE, Rogerson C, Duszynski T, Barron MA, Mayer D, Chavez C, Weber ZA, Reese SE, Essien I, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Koppolu P, Mak J, Kautz A, DeCuir J, Wiegand RE, Payne AB, Link-Gelles R. Irving SA, et al. Among authors: ball sw. MMWR Morb Mortal Wkly Rep. 2025 Dec 11;74(40):607-614. doi: 10.15585/mmwr.mm7440a1. MMWR Morb Mortal Wkly Rep. 2025. PMID: 41379943 Free PMC article.
Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women.
Ciesla AA, Lazariu V, Watts JA, Vazquez-Benitez G, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva M, Sheffield T, Bride D, Van Otterloo J, Arndorfer J, Naleway AL, Koppolu P, Fireman B, Hansen J, Timbol J, Dixon BE, Rogerson C, Fadel W, Barron MA, Mayer D, Chavez C, Zhuang Y, Cheung A, Reichle L, Natarajan K, Payne AB, Link-Gelles R, Zerbo O. Ciesla AA, et al. Among authors: ball sw. Obstet Gynecol. 2026 Apr 1;147(4):569-573. doi: 10.1097/AOG.0000000000006145. Epub 2025 Dec 11. Obstet Gynecol. 2026. PMID: 41380159
Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years: Results and Experience From a Randomized, Double-Blind Trial.
Grant L, Whitaker JA, Yoon SK, Lutrick K, Bhargava S, Brown CP, Zaragoza E, Fink RV, Meece J, Wielgosz K, El Sahly H, Hegmann KT, Lowe AA, Southworth A, Tatum T, Ball SW, Levine MZ, Thiese MS, Battan-Wraith S, Barnes J, Phillips AL, Fry AM, Dawood FS; Randomized Assessment of Influenza Vaccine Efficacy Network (RAIVEN). Grant L, et al. Among authors: ball sw. Open Forum Infect Dis. 2024 Sep 26;11(10):ofae559. doi: 10.1093/ofid/ofae559. eCollection 2024 Oct. Open Forum Infect Dis. 2024. PMID: 39416990 Free PMC article. Clinical Trial.
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.
Payne AB, Battan-Wraith S, Rowley EAK, Stockwell MS, Tartof SY, Dascomb K, Irving SA, Dixon B, Ball SW, Tenforde MW, Vazquez-Benitez G, Stephens AB, Han J, Natarajan K, Salas SB, Bezi C, Sy LS, Lewin B, Sheffield T, Arndorfer J, Bride D, Van Otterloo J, Naleway AL, Koppolu PD, Grannis S, Fadel W, Rogerson C, Duszynski T, Reese SE, Mitchell PK, Chickery S, Moline HL, Najdowski M, Ciesla AA, Reeves EL, DeSilva M, Fleming-Dutra KE, Link-Gelles R. Payne AB, et al. Among authors: ball sw. Lancet Reg Health Am. 2025 Aug 6;49:101196. doi: 10.1016/j.lana.2025.101196. eCollection 2025 Sep. Lancet Reg Health Am. 2025. PMID: 41040536 Free PMC article.
Reply to Skowronski, De Serres, and Orenstein.
Thompson MG, Jackson ML, Regan A, Katz MA, Kwong JC, Ball SW, Simmonds K, Klein NP, Naleway A. Thompson MG, et al. Among authors: ball sw. Clin Infect Dis. 2019 Aug 30;69(6):1085-1086. doi: 10.1093/cid/ciz115. Clin Infect Dis. 2019. PMID: 30753401 No abstract available.
63 results